Skip to main content

Table 2 Highlights of ECL antibody assay validation characteristics

From: Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia

PC

PC1: Rabbit Anti-InO

PC2: Rabbit Anti-CMC (Payload) Antibody

PCs in biological matrix (drug tolerance and confirmation assay)

HPC 1:75 in 100% serum

LPC 1:750 in 100% serum

Intra-assay precision (%CV of endpoint log10 titer)

0.8%

Inter-assay precision (%CV of endpoint log10 titer)

1.2%

Sensitivity (affinity-purified polyclonal antibody)

215 ng/mL (in 100% serum)

Drug interference

PC at high concentration was detected in the presence of 50 μg/mL; PC at low concentration was detected in the presence of 5.0 μg/mL

Matrix selectivity (recovery) with PCs

All unspiked samples generated signal below the cut point showing negative result; 90% of ALL lots tested had recovery between 75% and 125% for both control antibodies

Stability (PC1 and PC2)

23-h ambient temperature

5 freeze/thaw cycles at − 70 °C and − 20 °C

Stability (biotinylated and ruthenylated InO freeze/thaw stability)

5 freeze/thaw cycles at − 70 °C

  1. %CV coefficient of variation, ALL acute lymphoblastic leukemia, CMC calicheamicin, ECL electrochemiluminescence, HPC high positive control, InO inotuzumab ozogamicin, LPC low positive control, PC positive control